CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print April 15, 2009
CA Cancer J Clin 2009
doi: 10.3322/caac.20009
© 2009 American Cancer Society
This Article
Right arrow Full Text Freely available
Right arrow Freely available CME: Take the course for this article:
 Advances in Understanding and Management of Myeloproliferative Neoplasms
Right arrow FREE NURSING CONTACT HOURS
Right arrow All Versions of this Article:
caac.20009v1
59/3/171    most recent
Right arrow Submit a letter to the editor
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vannucchi, A. M.
Right arrow Articles by Tefferi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vannucchi, A. M.
Right arrow Articles by Tefferi, A.

Advances in understanding and management of myeloproliferative neoplasms

Alessandro M. Vannucchi, MD1, Paola Guglielmelli, MD2 and Ayalew Tefferi, MD3

1Associate Professor of Hematology, Department of Hematology, University of Florence, Florence, Italy
2Research Fellow at the Department of Hematology, University of Florence, Florence, Italy
3Professor of Medicine and Hematology, Mayo Clinic College of Medicine, Rochester, NY

Corresponding authors: Alessandro M. Vannucchi, MD, Hematology Unit, Dip. Area Critica, University of Florence, Viale Morgagni 85, 50134 Florence, Italy; amvannucchi{at}unifi.it and Ayalew Tefferi, MD, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905; tefferi.ayalew{at}mayo.edu

To earn free CME credit or nursing contact hours for successfully completing the online quiz based on this article, go to http://CME.AmCancerSoc.org.

DISCLOSURES: This study was supported by Associazione Italiana per la Ricerca sul Cancro, Milano; Istituto Toscano Tumori; MIUR (COFIN 2006067001_003). The authors report no conflicts of interest.

According to the 2008 World Health Organization classification system for hematologic malignancies, the myeloproliferative neoplasms (MPN) include chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, primary myelofibrosis, mastocytosis, chronic eosinophilic leukemia-not otherwise specified, chronic neutrophilic leukemia, and "MPN, unclassifiable." All of these clinicopathologic entities are characterized by stem cell-derived clonal myeloproliferation, and their phenotypic diversity is ascribed to the occurrence of distinct oncogenic events. In the last 4 years, new JAK2 and MPL mutations have been added to previously described ABL and KIT mutations as molecular markers of disease in MPN. These discoveries have markedly simplified the approach to clinical diagnosis and have also provided molecular targets for the development of small-molecule drugs. In the current article, the authors provide a clinically oriented overview of MPNs in terms of their molecular pathogenesis, classification, diagnosis, and management. CA Cancer J Clin 2009. © 2009 American Cancer Society, Inc.




This article has been cited by other articles:


Home page
 BloodHome page
F. Passamonti, F. Cervantes, A. M. Vannucchi, E. Morra, E. Rumi, A. Pereira, P. Guglielmelli, E. Pungolino, M. Caramella, M. Maffioli, et al.
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Blood, March 4, 2010; 115(9): 1703 - 1708.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Dragani, S. Pascale, A. Recchiuti, D. Mattoscio, S. Lattanzio, G. Petrucci, L. Mucci, E. Ferrante, A. Habib, F. O. Ranelletti, et al.
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy
Blood, February 4, 2010; 115(5): 1054 - 1061.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Barbui, A. Carobbio, F. Cervantes, A. M. Vannucchi, P. Guglielmelli, E. Antonioli, A. Alvarez-Larran, A. Rambaldi, G. Finazzi, and G. Barosi
Thrombosis in primary myelofibrosis: incidence and risk factors
Blood, January 28, 2010; 115(4): 778 - 782.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
L. Pieri, C. Bogani, P. Guglielmelli, M. Zingariello, R. A. Rana, N. Bartalucci, A. Bosi, and A. M. Vannucchi
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera
Haematologica, November 1, 2009; 94(11): 1537 - 1545.
[Abstract] [Full Text] [PDF]

eLetters:

Read all eLetters

Estrogen Receptor Might be an Important Factor for Myeloproliferative Neoplasms
Jie Yao, PhD, MD, et al.
CA Online, 28 Jul 2009 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH
Copyright © 2009 by American Cancer Society.